Literature DB >> 7641199

Inhibition of lymphoma growth in vivo by combined treatment with hydroxyethyl starch deferoxamine conjugate and IgG monoclonal antibodies against the transferrin receptor.

J D Kemp1, T Cardillo, B C Stewart, E Kehrberg, G Weiner, B Hedlund, P W Naumann.   

Abstract

Synergistic inhibition of hematopoietic tumor growth can be observed in vitro when the iron chelator deferoxamine (DFO) is used in combination with an IgG mAb against the anti-transferrin receptor antibody (ATRA). Our goal was to ascertain whether similar findings could be seen in vivo. A high molecular weight conjugate of deferoxamine, known as hydroxyethyl starch (HES) DFO or HES-DFO, was tested in conjunction with C2, a well-defined rat antimouse transferrin receptor mAb, against the 38C13 tumor in C3H/HeN mice. It was shown that while neither HES-DFO alone nor C2 alone produced consistent, significant inhibition of tumor growth, the combination of HES-DFO and C2 produced virtually complete inhibition of initial tumor outgrowth. The latter combination failed, however, to inhibit the growth of established tumors. It was then found that when C2 was used in conjunction with RL34, another IgG ATRA, the two ATRAS were themselves capable of causing synergistic inhibition of the growth of 38C13 in vitro. When the two IgG ATRAS were used together in vivo, regressions of established tumors were observed. Moreover, the addition of HES-DFO to the IgG ATRA pair then caused more frequent regressions. Although there was never any obvious toxicity seen with a single IgG ATRA, the use of the IgG ATRA pair was associated with sporadic mortality. In addition, although HES-DFO by itself was also not associated with any obvious toxicity, combined treatment with HES-DFO and a single ATRA resulted in death due to bacterial infection in about half of the mice after 10-15 days. Combined treatment with HES-DFO and the ATRA pair resulted in death attributed to infection in nearly all of the mice after 6 days. Thus, an iron deprivation treatment protocol with HES-DFO and IgG ATRAS produced both a significant antitumor effect and an increased risk of infection in a murine model system.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7641199

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  7 in total

1.  Tachpyridine, a metal chelator, induces G2 cell-cycle arrest, activates checkpoint kinases, and sensitizes cells to ionizing radiation.

Authors:  Jolyn Turner; Constantinos Koumenis; Timothy E Kute; Roy P Planalp; Martin W Brechbiel; Dillon Beardsley; Brooke Cody; Kevin D Brown; Frank M Torti; Suzy V Torti
Journal:  Blood       Date:  2005-07-12       Impact factor: 22.113

2.  Polymeric conjugates for drug delivery.

Authors:  Nate Larson; Hamidreza Ghandehari
Journal:  Chem Mater       Date:  2012-01-04       Impact factor: 9.811

3.  Differing sensitivity of tumor cells to apoptosis induced by iron deprivation in vitro.

Authors:  J Kovár; T Valenta; H Stýbrová
Journal:  In Vitro Cell Dev Biol Anim       Date:  2001 Jul-Aug       Impact factor: 2.416

4.  Identification of the di-pyridyl ketone isonicotinoyl hydrazone (PKIH) analogues as potent iron chelators and anti-tumour agents.

Authors:  Erika M Becker; David B Lovejoy; Judith M Greer; Ralph Watts; Des R Richardson
Journal:  Br J Pharmacol       Date:  2003-03       Impact factor: 8.739

5.  Deferasirox (ICL670A) effectively inhibits oesophageal cancer growth in vitro and in vivo.

Authors:  S J Ford; P Obeidy; D B Lovejoy; M Bedford; L Nichols; C Chadwick; O Tucker; G Y L Lui; D S Kalinowski; P J Jansson; T H Iqbal; D Alderson; D R Richardson; C Tselepis
Journal:  Br J Pharmacol       Date:  2013-03       Impact factor: 8.739

Review 6.  Recent Developments in Active Tumor Targeted Multifunctional Nanoparticles for Combination Chemotherapy in Cancer Treatment and Imaging.

Authors:  Micah D K Glasgow; Mahavir B Chougule
Journal:  J Biomed Nanotechnol       Date:  2015-11       Impact factor: 4.099

7.  Iron chelation cancer therapy using hydrophilic block copolymers conjugated with deferoxamine.

Authors:  Kana Komoto; Takahiro Nomoto; Sjaikhurrizal El Muttaqien; Hiroyasu Takemoto; Makoto Matsui; Yutaka Miura; Nobuhiro Nishiyama
Journal:  Cancer Sci       Date:  2020-11-29       Impact factor: 6.518

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.